Literature DB >> 20840586

Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis.

Uri Barash1, Victoria Cohen-Kaplan, Ilana Dowek, Ralph D Sanderson, Neta Ilan, Israel Vlodavsky.   

Abstract

Heparanase is an endo-β-D-glucuronidase capable of cleaving heparan sulfate side chains at a limited number of sites, yielding heparan sulfate fragments of still appreciable size. Importantly, heparanase activity correlates with the metastatic potential of tumor-derived cells, attributed to enhanced cell dissemination as a consequence of heparan sulfate cleavage and remodeling of the extracellular matrix and basement membrane underlying epithelial and endothelial cells. Similarly, heparanase activity is implicated in neovascularization, inflammation and autoimmunity, involving the migration of vascular endothelial cells and activated cells of the immune system. The cloning of a single human heparanase cDNA 10 years ago enabled researchers to critically approve the notion that heparan sulfate cleavage by heparanase is required for structural remodeling of the extracellular matrix, thereby facilitating cell invasion. Progress in the field has expanded the scope of heparanase function and its significance in tumor progression and other pathologies. Notably, although heparanase inhibitors attenuated tumor progression and metastasis in several experimental systems, other studies revealed that heparanase also functions in an enzymatic activity-independent manner. Thus, inactive heparanase was noted to facilitate adhesion and migration of primary endothelial cells and to promote phosphorylation of signaling molecules such as Akt and Src, facilitating gene transcription (i.e. vascular endothelial growth factor) and phosphorylation of selected Src substrates (i.e. endothelial growth factor receptor). The concept of enzymatic activity-independent function of heparanase gained substantial support by the recent identification of the heparanase C-terminus domain as the molecular determinant behind its signaling capacity. Identification and characterization of a human heparanase splice variant (T5) devoid of enzymatic activity and endowed with protumorigenic characteristics, elucidation of cross-talk between heparanase and other extracellular matrix-degrading enzymes, and identification of single nucleotide polymorphism associated with heparanase expression and increased risk of graft versus host disease add other layers of complexity to heparanase function in health and disease.
© 2010 The Authors Journal compilation © 2010 FEBS.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20840586      PMCID: PMC3000436          DOI: 10.1111/j.1742-4658.2010.07799.x

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  114 in total

1.  Requirement of the conserved, hydrophobic C-terminus region for the activation of heparanase.

Authors:  Ngit Shin Lai; Siro Simizu; Daiki Morisaki; Makoto Muroi; Hiroyuki Osada
Journal:  Exp Cell Res       Date:  2008-07-12       Impact factor: 3.905

Review 2.  Heparanase: one molecule with multiple functions in cancer progression.

Authors:  Israel Vlodavsky; Michael Elkin; Ghada Abboud-Jarrous; Flonia Levi-Adam; Liat Fuks; Itay Shafat; Neta Ilan
Journal:  Connect Tissue Res       Date:  2008       Impact factor: 3.417

Review 3.  Syndecan-1: a dynamic regulator of the myeloma microenvironment.

Authors:  Ralph D Sanderson; Yang Yang
Journal:  Clin Exp Metastasis       Date:  2007-11-20       Impact factor: 5.150

4.  Function of heparanase in prostate tumorigenesis: potential for therapy.

Authors:  Immanuel Lerner; Leah Baraz; Eli Pikarsky; Amichay Meirovitz; Evgeny Edovitsky; Tamar Peretz; Israel Vlodavsky; Michael Elkin
Journal:  Clin Cancer Res       Date:  2008-01-22       Impact factor: 12.531

5.  Synthesis and heparanase inhibitory activity of sulfated mannooligosaccharides related to the antiangiogenic agent PI-88.

Authors:  Jon K Fairweather; Edward Hammond; Ken D Johnstone; Vito Ferro
Journal:  Bioorg Med Chem       Date:  2007-10-18       Impact factor: 3.641

6.  Heparanase induces Akt phosphorylation via a lipid raft receptor.

Authors:  Olga Ben-Zaken; Svetlana Gingis-Velitski; Israel Vlodavsky; Neta Ilan
Journal:  Biochem Biophys Res Commun       Date:  2007-07-24       Impact factor: 3.575

7.  HLA-A2-restricted cytotoxic T lymphocyte epitopes from human heparanase as novel targets for broad-spectrum tumor immunotherapy.

Authors:  Ting Chen; Xu-Dong Tang; Yin Wan; Ling Chen; Song-Tao Yu; Zhen Xiong; Dian-Chun Fang; Guang-Ping Liang; Shi-Ming Yang
Journal:  Neoplasia       Date:  2008-09       Impact factor: 5.715

8.  H-2Kb-restricted CTL epitopes from mouse heparanase elicit an antitumor immune response in vivo.

Authors:  Xu-Dong Tang; Yin Wan; Ling Chen; Ting Chen; Song-Tao Yu; Zhen Xiong; Dian-Chun Fang; Guang-Ping Liang; Shi-Ming Yang
Journal:  Cancer Res       Date:  2008-03-01       Impact factor: 12.701

9.  Subcellular localization of human heparanase and its alternative splice variant in COS-7 cells.

Authors:  Mayumi Sato; Kana Amemiya; Sumio Hayakawa; Hiroshi Munakata
Journal:  Cell Biochem Funct       Date:  2008-08       Impact factor: 3.685

10.  Increased chemotactic migration and growth in heparanase-overexpressing human U251n glioma cells.

Authors:  Xin Hong; Feng Jiang; Steven N Kalkanis; Zheng Gang Zhang; Xuepeng Zhang; Xuguang Zheng; Hao Jiang; Tom Mikkelsen; Michael Chopp
Journal:  J Exp Clin Cancer Res       Date:  2008-07-22
View more
  89 in total

1.  Conformational changes of 1-4-glucopyranosyl residues of a sulfated C-C linked hexasaccharide.

Authors:  Alessia Coletti; Stefano Elli; Eleonora Macchi; Patrizia Galzerano; Leila Zamani; Marco Guerrini; Giangiacomo Torri; Elena Vismara
Journal:  Carbohydr Res       Date:  2014-02-25       Impact factor: 2.104

2.  Heparanase-mediated loss of nuclear syndecan-1 enhances histone acetyltransferase (HAT) activity to promote expression of genes that drive an aggressive tumor phenotype.

Authors:  Anurag Purushothaman; Douglas R Hurst; Claudio Pisano; Shuji Mizumoto; Kazuyuki Sugahara; Ralph D Sanderson
Journal:  J Biol Chem       Date:  2011-07-11       Impact factor: 5.157

3.  Significance of heparanase in cancer and inflammation.

Authors:  Israel Vlodavsky; Phillip Beckhove; Immanuel Lerner; Claudio Pisano; Amichai Meirovitz; Neta Ilan; Michael Elkin
Journal:  Cancer Microenviron       Date:  2011-08-03

4.  Heparanase and cancer progression: New directions, new promises.

Authors:  Gil Arvatz; Marina Weissmann; Neta Ilan; Israel Vlodavsky
Journal:  Hum Vaccin Immunother       Date:  2016-04-07       Impact factor: 3.452

5.  Heparanase regulates secretion, composition, and function of tumor cell-derived exosomes.

Authors:  Camilla A Thompson; Anurag Purushothaman; Vishnu C Ramani; Israel Vlodavsky; Ralph D Sanderson
Journal:  J Biol Chem       Date:  2013-02-21       Impact factor: 5.157

6.  Involvement of Heparanase in Empyema: Implication for Novel Therapeutic Approaches.

Authors:  Moshe Lapidot; Uri Barash; Yaniv Zohar; Yuval Geffen; Inna Naroditsky; Neta Ilan; Lael Anson Best; Israel Vlodavsky
Journal:  J Clin Cell Immunol       Date:  2015-02

7.  Overexpression of heparanase multiple antigenic peptide 2 is associated with poor prognosis in gastric cancer: Potential for therapy.

Authors:  Jun Zhang; Jianmin Yang; Xiaomei Han; Zhongsheng Zhao; Ling DU; Tong Yu; Huiju Wang
Journal:  Oncol Lett       Date:  2012-05-04       Impact factor: 2.967

8.  Heparan sulfate differences in rheumatoid arthritis versus healthy sera.

Authors:  Jenny K Sabol; Wei Wei; Marcos López-Hoyos; Youjin Seo; Armann Andaya; Julie A Leary
Journal:  Matrix Biol       Date:  2014-09-11       Impact factor: 11.583

Review 9.  Heparanase regulation of cancer, autophagy and inflammation: new mechanisms and targets for therapy.

Authors:  Ralph D Sanderson; Michael Elkin; Alan C Rapraeger; Neta Ilan; Israel Vlodavsky
Journal:  FEBS J       Date:  2016-11-16       Impact factor: 5.542

Review 10.  Involvement of heparanase in atherosclerosis and other vessel wall pathologies.

Authors:  Israel Vlodavsky; Miry Blich; Jin-Ping Li; Ralph D Sanderson; Neta Ilan
Journal:  Matrix Biol       Date:  2013-03-13       Impact factor: 11.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.